Search results for " biopharma"
Article
High-Throughput Process Development in an Historical Environment
The purpose of the Olympiad is to allow process developers to benchmark their internal HTPD workflows against peers in the biopharmaceutical industry and academy. The challenge in the very first HTPD …
Article
Setting Standards for Biotech Therapeutics in India
With the ongoing shift from small molecules to biologics, the Indian biopharmaceutical industry is also set to replicate the success received by the Indian pharmaceutical companies (Figure 1B) (1). Th…
Article
Healthcare Reform in China
Chinese healthcare reforms may be a double-edged sword for foreign companies.
Sep 1, 2014
By: Jane Wan
BioPharm International
Volume 27, Issue 9, pp. 8-12
On March 25, 2014, the…
Article
Pharma Investments Reflect Key Industry Trends
18-22
Numerous trends in the pharmaceutical industry, and particularly in the biopharmaceutical sector, are leading to the need for smaller-capacity production facilities, which in turn is affect…
Article
Relationship Building at Top of Mind for Clients
As results from BioPlan Associates’ 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (1) show, however, it’s no longer enough for CMOs to lay claim to technolog…
Article
A Q&A With Phil Lester, co-organizer of the HTPD Conference
The 3rd HTPD Conference will take place this October, in Siena, Italy. Process Development Forum spoke with Phil Lester, one of the principal organizers of the conference.
PDF: This is the third…
Article
Single-Domain Antibodies for Brain Targeting
With 25 mAb products on the market and more than 100 undergoing clinical trials (1-3), it is evident that engineered antibodies have come of age as biopharmaceuticals (4).
Intact antibodies (immun…
Article
Q&A with Industry Leader Konstantin Konstantinov, Genzyme Vice-President
This week we speak with Konstantin Konstantinov, Genzyme Vice-President Late Stage Process Development, about developments in continuous processing.
Q: You’re part of an upcoming sym…
Article
Monoclonal Antibodies Key to Unlocking the Biosimilars Market
“Since 2002, we have made significant investments in facilities, human resources, and technology to become a global and innovative biopharmaceutical company,” he says.
Need for clear regulatory pa…
Article
Q&A with Industry Leaders: Rita Peters
With additional product lines through acquisition or innovation, many suppliers emphasized capabilities of providing end-to-end technologies, equipment and support to the biopharmaceutical manufacturi…